Glucagon-like peptide-1 (GLP-1) receptor agonists are a family of antihyperglycemic drugs that have demonstrated potent HbA1c reduction, low risk of hypoglycemia, with associated weight reduction, and proven cardiovascular and renal benefits.24 In this review we describe this type of drugs, their cardiovascular and renal benefits, as well as their clinical potential in patients with DKD, especially with the new oral semaglutide formulation, now available on the market
The challenge isnt simply creating a peptide that can target the right biological system, but rather getting the delicate molecule to the correct place in the body intact to work its magic, Amiji said
I didnt crave my favorite chicken alfredo any more, nor did I crave any other food that sounded good or I saw on TV
Currently, research is also underway to expand indications such as diabetes accompanying obesity, cardiovascular disease, and sleep apnea.